Regulatory T Cells Along the Pancreatitis–Pancreatic Cancer Continuum: Context-Dependent Immune Control and Therapeutic Opportunities Authors: Hongmei Li, Pingping Wang, Hongsuo Chen, Chi Wang, Abdullah Al-Danakh, Zhenyu Jiang Published: 2026 ABSTRACT AbstractRegulatory T cells (Tregs) are essential for maintaining immune tolerance and limiting collateral tissue injury during inflammation. In pancreatic diseases, however, Treg function is highly context-dependent: protective in acute inflammatory settings by restraining excessive immune activation, yet potentially pathogenic by fostering immunosuppression and immune escape in pancreatic ductal adenocarcinoma (PDAC). Acute pancreatitis (AP), chronic pancreatitis (CP), and PDAC share overlapping immune microenvironmental features, including cytokine-driven T-cell reprogramming, barrier dysfunction–associated microbial translocation, and stromal–immune crosstalk. Understanding Treg behaviour along the pancreatitis–PDAC continuum requires deciphering context-dependent immune microenvironmental mechanisms that shift from protective regulation to tumour-promoting immunosuppression. Recent evidence highlights that indiscriminate Treg depletion may paradoxically accelerate pancreatic tumorigenesis in specific settings, underscoring the need to resolve Treg heterogeneity, tissue residency, and stage-specific roles. In this review, we summarise current mechanistic insights into Treg-mediated regulation in AP and CP (including Th17/Treg balance and fibrosis-associated immune networks) and in PDAC (including Treg phenotypic diversity and interactions with myeloid cells and stroma). We further discuss emerging therapeutic strategies that modulate Tregs directly or indirectly, and propose a translational framework for aligning Treg-targeted interventions with disease stage and immune context to improve outcomes in pancreatic inflammation and cancer. Introduction Pancreatic diseases, including acute pancreatitis (AP), chronic pancreatitis (CP), and pancreatic ductal adenocarcinoma (PDAC), represent a disease continuum ranging from acute inflammation through chronic fibrosis to malignancy. Their pathogenesis involves complex interplay among genetic susceptibility, environmental exposures, metabolic stress, and immune dysregulation.1,2 Increasing evidence indicates that immune imbalance—particularly aberrant T-cell responses—plays a central role across this spectrum.3,4 AP is an acute inflammatory condition triggered by premature activation of digestive enzymes within pancreatic acinar cells, initiating a cascade of autodigestion, cellular necrosis, and release of damage-associated molecular patterns (DAMPs) that activate innate immune receptors, recruiting neutrophils and macrophages to the pancreas. In severe cases, a systemic inflammatory response syndrome (SIRS) can progress to multiorgan failure.3,4 Although most AP episodes resolve spontaneously, severe AP carries high mortality, often driven by secondary infections and immune dysfunction rather than pancreatic injury alone.4 CP, by contrast, is a progressive fibroinflammatory disease resulting from repeated or sustained pancreatic injury, reflecting failure to resolve inflammation and leading to irreversible acinar cell loss, persistent activation of pancreatic stellate cells (PSCs), extensive stromal remodelling, and ultimately exocrine and endocrine insufficiency.2,5–7 Chronic pain, malnutrition, and diabetes are common clinical sequelae. Critically, CP is an established risk factor for PDAC, supporting the concept that persistent inflammation promotes malignant transformation.8–11 PDAC remains one of the most lethal malignancies, with a five-year survival rate below 10% despite advances in surgery and chemotherapy.8–12 Late diagnosis is a major contributor to poor prognosis, as most patients present with advanced, unresectable disease.13–16 The PDAC tumour microenvironment (TME) is hallmarked by dense desmoplasia, hypovascularity, and profound immunosuppression, collectively blunting anti-tumour immunity.17,18 A comparative overview of the key immunological features distinguishing AP, CP, and PDAC is provided in Table 1. A schematic overview of immune-cell functions across AP, CP, and PDAC is shown in Figure 1.Table 1Comparison of Immunological Features Across Acute Pancreatitis, Chronic Pancreatitis, and Pancreatic Ductal AdenocarcinomaImmunological FeatureAcute Pancreatitis (AP)Chronic Pancreatitis (CP)Pancreatic Ductal Adenocarcinoma (PDAC)Dominant immune cellsNeutrophils, macrophages, Th17 cellsTregs, M2-polarised macrophages, fibroblasts, Th2 cellsTregs, myeloid-derived suppressor cells (MDSCs), M2 tumour-associated macrophages (TAMs), exhausted T cellsTh17 / Treg balanceTh17 ↑ early, Treg ↑ late (dynamic shift)Treg ↑ (generally protective)Treg ↑↑ (pathogenic, tumour-promoting)Cytokine milieuIL-6, IL-17, TNF-α, IL-1β ↑TGF-β, IL-10, IL-4, IL-13 ↑TGF-β, IL-35, IL-10, VEGF, IL-6 ↑Inflammation resolutionYes – usually self-limitingNo – persistent inflammationNo – progressive and dysregulatedFibrosis / stromal reactionMinimal to noneSevere fibrosis (pancreatic stellate cell activation)Severe desmoplasia (dense stromal barrier)Immune suppressionTransient, compensatory (prevents excessive damage)Chronic, regulatory (limits fibrosis but may impair regeneration)Profound, tumour-driven (promotes immune escape)Treg functional roleRestrains excessive inflammation (but excess Tregs worsen barrier function)Suppresses type-2 immunity and fibrosis (protective)Promotes immune evasion, suppresses cytotoxic T cells, supports tumour progressionEffector T-cell statusActivated (Th1, Th17, CD8⁺)Partially suppressedFunctionally exhausted, spatially excludedAntigen presentationEnhanced (DAMPs, PAMPs)Chronic, low-gradeImpaired (dysfunctional dendritic cells, MHC downregulation)Microbial influenceBacterial translocation from gut (TLR5 signalling)Possible low-grade dysbiosisIntratumoural microbiota, barrier dysfunction Figure 1Schematic overview of immune cell functions across acute pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma. The figure illustrates the dominant immune cell populations and functional immune shifts along the pancreatitis–pancreatic cancer continuum. In acute pancreatitis, neutrophils, macrophages, and Th17 cells drive acute inflammation, cytokine release, and neutrophil recruitment, while Tregs restrain excessive inflammatory injury. In chronic pancreatitis, Tregs, M2-polarised macrophages, and pancreatic stellate cells contribute to tissue remodelling and fibrosis, with Tregs limiting excessive fibrogenic immune activation. In pancreatic ductal adenocarcinoma, expanded Tregs, myeloid-derived suppressor cells, M2 tumour-associated macrophages, and exhausted CD8⁺ T cells dominate the tumour microenvironment, promoting immune escape, tumour progression, and resistance to immunotherapy.The infographic illustrates the disease continuum from Acute Pancreatitis (AP) to Chronic Pancreatitis (CP) and Pancreatic Ductal Adenocarcinoma (PDAC). In AP, dominant cells include neutrophils, macrophages (M1) and Th17 cells, with key functions like inflammation, cytokine release (IL-6, IL-17, TNF-α) and inflammation resolution. Tregs restrain excessive inflammation. In CP, dominant cells are Tregs, M2 macrophages and fibroblasts/PSCs, with functions like fibrosis, tissue remodeling and cytokine production (TGF-β, IL-10). Tregs suppress fibrosis, leading to persistent inflammation and risk of malignant transformation. In PDAC, dominant cells include expanded Tregs, MDSCs, M2 TAMs and exhausted CD8+ T cells, with functions like immune suppression, escape and tumor cell survival. Tregs suppress CD8+ T cells, contributing to tumor progression and immunotherapy resistance. The continuum shows increasing immune suppression and Treg dominance.Infographic of disease continuum from acute pancreatitis to pancreatic ductal adenocarcinoma. Table 1Comparison of Immunological Features Across Acute Pancreatitis, Chronic Pancreatitis, and Pancreatic Ductal AdenocarcinomaImmunological FeatureAcute Pancreatitis (AP)Chronic Pancreatitis (CP)Pancreatic Ductal Adenocarcinoma (PDAC)Dominant immune cellsNeutrophils, macrophages, Th17 cellsTregs, M2-polarised macrophages, fibroblasts, Th2 cellsTregs, myeloid-derived suppressor cells (MDSCs), M2 tumour-associated macrophages (TAMs), exhausted T cellsTh17 / Treg balanceTh17 ↑ early, Treg ↑ late (dynamic shift)Treg ↑ (generally protective)Treg ↑↑ (pathogenic, tumour-promoting)Cytokine milieuIL-6, IL-17, TNF-α, IL-1β ↑TGF-β, IL-10, IL-4, IL-13 ↑TGF-β, IL-35, IL-10, VEGF, IL-6 ↑Inflammation resolutionYes – usually self-limitingNo – persistent inflammationNo – progressive and dysregulatedFibrosis / stromal reactionMinimal to noneSevere fibrosis (pancreatic stellate cell activation)Severe desmoplasia (dense stromal barrier)Immune suppressionTransient, compensatory (prevents excessive damage)Chronic, regulatory (limits fibrosis but may impair regeneration)Profound, tumour-driven (promotes immune escape)Treg functional roleRestrains excessive inflammation (but excess Tregs worsen barrier function)Suppresses type-2 immunity and fibrosis (protective)Promotes immune evasion, suppresses cytotoxic T cells, supports tumour progressionEffector T-cell statusActivated (Th1, Th17, CD8⁺)Partially suppressedFunctionally exhausted, spatially excludedAntigen presentationEnhanced (DAMPs, PAMPs)Chronic, low-gradeImpaired (dysfunctional dendritic cells, MHC downregulation)Microbial influenceBacterial translocation from gut (TLR5 signalling)Possible low-grade dysbiosisIntratumoural microbiota, barrier dysfunction Comparison of Immunological Features Across Acute Pancreatitis, Chronic Pancreatitis, and Pancreatic Ductal Adenocarcinoma Schematic overview of immune cell functions across acute pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma. The figure illustrates the dominant immune cell populations and functional immune shifts along the pancreatitis–pancreatic cancer continuum. In acute pancreatitis, neutrophils, macrophages, and Th17 cells drive acute inflammation, cytokine release, and neutrophil recruitment, while Tregs restrain excessive inflammatory injury. In chronic pancreatitis, Tregs, M2-polarised macrophages, and pancreatic stellate cells contribute to tissue remodelling and fibrosis, with Tregs limiting excessive fibrogenic immune activation. In pancreatic ductal adenocarcinoma, expanded Tregs, myeloid-derived suppressor cells, M2 tumour-associated macrophages, and exhausted CD8⁺ T cells dominate the tumour microenvironment, promoting immune escape, tumour progression, and resistance to immunotherapy. Across AP, CP, and PDAC, genetic variants (eg, PRSS1, SPINK1, CFTR in pancreatitis; KRAS, TP53, CDKN2A, SMAD4 in PDAC) modulate disease susceptibility. Environmental exposures—including alcohol, smoking, and dietary factors—interact with these genetic backgrounds. Metabolic stress, particularly obesity and diabetes, further amplifies inflammation and may accelerate the transition from CP to PDAC. Immune dysregulation, especially altered T-cell homeostasis, represents a unifying mechanism linking these factors to disease outcomes.1,2 Among immune regulators, regulatory T cells (Tregs) play a pivotal role in maintaining immune tolerance and preventing excessive tissue damage under physiological conditions.19,20 Classically defined by CD4, CD25, and the transcription factor Foxp3, Tregs suppress immune responses through multiple mechanisms, including immunosuppressive cytokines (IL-10, TGF-β), metabolic competition, cytolysis, and inhibitory receptor signalling (eg, CTLA-4).20–23 Dysregulation of Treg number, phenotype, or function can profoundly alter disease trajectories. In pancreatic diseases, Tregs exhibit context-dependent and stage-specific roles. During AP, Treg expansion may limit excessive inflammation, but excessive or mistimed immunosuppression can impair mucosal barrier integrity, promote bacterial translocation, and exacerbate disease severity.24,25 In CP, Tregs control chronic immune activation and fibrosis by suppressing type-2 immune responses and inflammatory myeloid activity.26,27 In PDAC, Tregs are frequently enriched within tumour tissue and draining lymph nodes, where they contribute to immune evasion and immunotherapy resistance—yet paradoxically may restrain tumour-promoting inflammation in specific contexts.17,28–30 Despite accumulating evidence, several critical knowledge gaps remain. First, the heterogeneity of Treg subsets across AP, CP, and PDAC is poorly characterised; single-cell transcriptomic studies have revealed unexpected diversity, but functional validation is lacking. Second, the spatial organisation of Tregs within inflamed or neoplastic pancreatic tissue—particularly their proximity to effector T cells, dendritic cells, and stromal elements—remains largely unexplored. Third, therapeutic targeting of Tregs faces a fundamental challenge: how to abrogate tumour-promoting Treg activity without inducing systemic immune dysregulation or autoimmunity. Fourth, the immunological transition from CP to PDAC remains incompletely understood; it is unclear whether Tregs facilitate, delay, or passively accompany malignant transformation.17,31 Recent studies further reveal that Tregs in PDAC are phenotypically and functionally heterogeneous, with distinct subpopulations exerting divergent effects on tumour progression and patient prognosis.32,33 Notably, experimental Treg depletion does not uniformly enhance anti-tumor immunity and may, under specific conditions, accelerate pancreatic carcinogenesis by reshaping CD4⁺ T-cell responses and inflammatory signaling networks.17,31 These findings challenge the simplistic view of Tregs as universally deleterious in cancer and underscore the necessity of precise, context-aware immunomodulation. Major T-cell subsets, their canonical markers, and disease-relevant functions are summarized in Table 2.Table 2Major T-Cell Subsets, Canonical Markers, Immunological Functions, and Their Relevance Across Pancreatic DiseasesT-Cell SubsetCanonical MarkersKey FunctionsRelevance to Pancreatic DiseasesNaïve T cellsCD3⁺ CD4⁺ or CD8⁺ CD45RA⁺ CCR7⁺Antigen-inexperienced precursors that circulate between blood and secondary lymphoid organsReduced activation and impaired priming observed in pancreatic cancer due to immunosuppressive tumour microenvironmentCD4⁺ Helper T cells (Th cells)CD3⁺ CD4⁺Coordinate immune responses via cytokine secretion and immune cell crosstalkDysregulated differentiation (Th1/Th2/Th17 imbalance) contributes to inflammation severity in AP and fibrosis in CPTh17 cellsCD4⁺ RORγt⁺ IL-17A⁺Promote inflammation, neutrophil recruitment, and barrier immunityTh17/Treg imbalance is associated with disease severity and bacterial translocation in severe APCD8⁺ Cytotoxic T lymphocytes (CTLs)CD3⁺ CD8⁺ Granzyme B⁺ Perforin⁺Direct killing of virus-infected and malignant cellsFunctionally exhausted and spatially excluded in PDAC, contributing to immune escapeRegulatory T cells (Tregs)CD4⁺ CD25⁺ Foxp3⁺ (± CTLA-4, Helios)Suppress immune activation; maintain immune tolerance via cytokines, cell contact, and metabolic controlProtective in limiting inflammation in AP/CP; enriched in PDAC where they promote immunosuppression and therapy resistanceCentral memory T cells (Tcm)CD3⁺ CD45RO⁺ CCR7⁺ CD62L⁺Long-lived memory cells with high proliferative potentialReduced effective memory responses in pancreatic cancer due to chronic antigen exposureEffector memory T cells (Tem)CD3⁺ CD45RO⁺ CCR7− CD62L−Rapid effector function in peripheral tissues upon antigen re-encounterAltered tissue residency and exhaustion observed in PDAC microenvironmentExhausted T cellsCD8⁺ PD-1⁺ TIM-3⁺ LAG-3⁺ (± TOX)Reduced cytotoxicity and cytokine production due to chronic stimulationDominant phenotype in PDAC, contributing to resistance to immune checkpoint blockadeγδ T cellsCD3⁺ γδTCR⁺Rapid innate-like immune surveillance and tissue homeostasisDual role reported: pro-inflammatory in pancreatitis; context-dependent effects in PDACNatural killer T (NKT) cellsCD3⁺ CD1d-restricted (eg, Vα24-Jα18 in humans)Bridge innate and adaptive immunity; lipid antigen recognitionModulate inflammation and anti-tumour immunity in pancreatic disease, though often functionally suppressed in PDACAbbreviations: AP, acute pancreatitis; CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma; TCR, T-cell receptor; Foxp3, forkhead box P3; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; LAG-3, lymphocyte activation gene-3. Table 2Major T-Cell Subsets, Canonical Markers, Immunological Functions, and Their Relevance Across Pancreatic DiseasesT-Cell SubsetCanonical MarkersKey FunctionsRelevance to Pancreatic DiseasesNaïve T cellsCD3⁺ CD4⁺ or CD8⁺ CD45RA⁺ CCR7⁺Antigen-inexperienced precursors that circulate between blood and secondary lymphoid organsReduced activation and impaired priming observed in pancreatic cancer due to immunosuppressive tumour microenvironmentCD4⁺ Helper T cells (Th cells)CD3⁺ CD4⁺Coordinate immune responses via cytokine secretion and immune cell crosstalkDysregulated differentiation (Th1/Th2/Th17 imbalance) contributes to inflammation severity in AP and fibrosis in CPTh17 cellsCD4⁺ RORγt⁺ IL-17A⁺Promote inflammation, neutrophil recruitment, and barrier immunityTh17/Treg imbalance is associated with disease severity and bacterial translocation in severe APCD8⁺ Cytotoxic T lymphocytes (CTLs)CD3⁺ CD8⁺ Granzyme B⁺ Perforin⁺Direct killing of virus-infected and malignant cellsFunctionally exhausted and spatially excluded in PDAC, contributing to immune escapeRegulatory T cells (Tregs)CD4⁺ CD25⁺ Foxp3⁺ (± CTLA-4, Helios)Suppress immune activation; maintain immune tolerance via cytokines, cell contact, and metabolic controlProtective in limiting inflammation in AP/CP; enriched in PDAC where they promote immunosuppression and therapy resistanceCentral memory T cells (Tcm)CD3⁺ CD45RO⁺ CCR7⁺ CD62L⁺Long-lived memory cells with high proliferative potentialReduced effective memory responses in pancreatic cancer due to chronic antigen exposureEffector memory T cells (Tem)CD3⁺ CD45RO⁺ CCR7− CD62L−Rapid effector function in peripheral tissues upon antigen re-encounterAltered tissue residency and exhaustion observed in PDAC microenvironmentExhausted T cellsCD8⁺ PD-1⁺ TIM-3⁺ LAG-3⁺ (± TOX)Reduced cytotoxicity and cytokine production due to chronic stimulationDominant phenotype in PDAC, contributing to resistance to immune checkpoint blockadeγδ T cellsCD3⁺ γδTCR⁺Rapid innate-like immune surveillance and tissue homeostasisDual role reported: pro-inflammatory in pancreatitis; context-dependent effects in PDACNatural killer T (NKT) cellsCD3⁺ CD1d-restricted (eg, Vα24-Jα18 in humans)Bridge innate and adaptive immunity; lipid antigen recognitionModulate inflammation and anti-tumour immunity in pancreatic disease, though often functionally suppressed in PDACAbbreviations: AP, acute pancreatitis; CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma; TCR, T-cell receptor; Foxp3, forkhead box P3; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; LAG-3, lymphocyte activation gene-3. Major T-Cell Subsets, Canonical Markers, Immunological Functions, and Their Relevance Across Pancreatic Diseases Abbreviations: AP, acute pancreatitis; CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma; TCR, T-cell receptor; Foxp3, forkhead box P3; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; LAG-3, lymphocyte activation gene-3. Given the shared immunological features of AP, CP, and PDAC—and the central yet paradoxical role of Tregs across these conditions—a comprehensive synthesis of Treg-mediated immune regulation in pancreatic diseases is urgently needed. In this review, we summarize current advances in Treg functions, mechanisms, and heterogeneity in AP, CP, and PDAC. We further discuss emerging therapeutic strategies targeting Treg-associated pathways and propose a translational framework for aligning Treg-targeted interventions with disease stage and immune context. Regulatory T Cells: Biology, Heterogeneity, and Context-Dependent Functions Identity and Functional Plasticity of Regulatory T Cells Regulatory T cells (Tregs) are a specialised subset of CD4⁺ T lymphocytes that play a central role in maintaining immune tolerance and preventing excessive or self-destructive immune responses. Canonically, Tregs are characterised by high expression of CD25 and the lineage-defining transcription factor Foxp3, which orchestrates their suppressive phenotype and stabilises Treg identity at the transcriptional and epigenetic levels.19,20 Loss of Foxp3 expression or functional instability of Tregs results in severe systemic autoimmunity, underscoring their indispensable role in immune homeostasis. Tregs are not a uniform population. They can be broadly categorised into thymus-derived Tregs (tTregs), which emerge during thymic selection and enforce central tolerance, and peripherally induced Tregs (pTregs), which differentiate from conventional CD4⁺ T cells in peripheral tissues in response to antigenic stimulation and cytokine cues such as TGF-β.20,23 This distinction is particularly relevant in tissues exposed to persistent inflammation or environmental antigens—such as the pancreas—where pTregs contribute dynamically to local immune regulation. Beyond their developmental origin, Tregs exhibit substantial functional and phenotypic heterogeneity shaped by tissue residency, inflammatory signals, metabolic constraints, and cellular interactions within the immune microenvironment. Recent advances in single-cell transcriptomics and spatial profiling have revealed that Tregs adapt their suppressive programs to local contexts, acquiring tissue-specific features that influence disease outcomes.31,34 These findings challenge the notion of Tregs as static suppressors and instead position them as flexible regulators whose effects depend on timing, location, and surrounding immune networks. Mechanisms of Immune Regulation Mediated by Tregs Tregs suppress immune responses through multiple, often overlapping mechanisms that collectively fine-tune immune activation rather than simply shutting it down. One major pathway involves the secretion of immunosuppressive cytokines, including IL-10, TGF-β, and IL-35, which dampen effector T-cell proliferation, inhibit antigen-presenting cell maturation, and limit inflammatory cytokine production.21,23 In parallel, Tregs exert contact-dependent suppression via inhibitory receptors such as CTLA-4, which downregulate CD80/CD86 expression on dendritic cells, thereby reducing co-stimulatory signalling required for T-cell activation.20,22 Metabolic regulation represents another critical dimension of Treg function. By consuming IL-2 through high CD25 expression, Tregs deprive effector T cells of this essential growth factor. In addition, Tregs modulate the metabolic microenvironment by generating adenosine and tolerogenic metabolites that further restrain immune activation.23 Cytolytic mechanisms, including perforin- and granzyme-mediated killing of activated immune cells, have also been described in specific contexts, highlighting the versatility of Treg-mediated control. The principal mechanisms by which regulatory T cells suppress immune responses are illustrated in Figure 2.20–23 Figure 2Regulatory T cells mediate immune suppression through multiple complementary mechanisms. Regulatory T cells (Tregs) suppress immune activation through immunosuppressive cytokine secretion, cytokine deprivation, inhibitory receptor signalling, metabolic disruption, and cytolytic pathways. Tregs secrete IL-10, TGF-β, and IL-35 to inhibit effector T-cell activation and antigen-presenting cell function; consume IL-2 through high CD25/IL-2R expression; suppress dendritic-cell co-stimulation through CTLA-4–CD80/CD86 interactions; generate adenosine through CD39/CD73-mediated ATP/ADP metabolism; and induce target-cell apoptosis through perforin and granzyme B. PD-1/PD-L1 signalling may further contribute to inhibitory immune regulation.The diagram illustrates Treg cell functions, highlighting six key mechanisms. 1) Immunosuppressive cytokine secretion involves IL-10, TGF-beta and IL-35, leading to apoptosis via granzyme and perforin. 2) Cytokine deprivation through IL-2 consumption affects effector T cells, causing apoptosis. 3) Inhibitory receptor signaling via CTLA-4 impacts dendritic cells by interacting with CD80/CD86. 4) Metabolic disruption through adenosine generation involves CD39 and CD73 converting ATP/ADP to AMP and adenosine, affecting effector T cells via A subscript 2A receptors. 5) Cytolysis through perforin and granzymes targets T cells, NK cells and dendritic cells, inducing apoptosis. 6) Inhibitory receptor signaling through PD-1/PD-L1 affects B cells. Arrows indicate Treg-mediated actions and inhibition of target cell functions.Treg cells suppress immunity via cytokines, signaling and cytolysis impacting T, B and dendritic cells. Regulatory T cells mediate immune suppression through multiple complementary mechanisms. Regulatory T cells (Tregs) suppress immune activation through immunosuppressive cytokine secretion, cytokine deprivation, inhibitory receptor signalling, metabolic disruption, and cytolytic pathways. Tregs secrete IL-10, TGF-β, and IL-35 to inhibit effector T-cell activation and antigen-presenting cell function; consume IL-2 through high CD25/IL-2R expression; suppress dendritic-cell co-stimulation through CTLA-4–CD80/CD86 interactions; generate adenosine through CD39/CD73-mediated ATP/ADP metabolism; and induce target-cell apoptosis through perforin and granzyme B. PD-1/PD-L1 signalling may further contribute to inhibitory immune regulation. Importantly, Treg-mediated suppression is not inherently pathological. Under physiological conditions and during acute inflammatory responses, these mechanisms prevent uncontrolled immune escalation and collateral tissue damage. However, when Treg activity becomes excessive, mistimed, or spatially misdirected, immune suppression may hinder pathogen clearance, disrupt epithelial barrier integrity, or permit malignant cells to evade immune surveillance. Context-Dependent Roles of Tregs in Inflammation and Cancer The functional outcome of Treg activity is highly context-dependent and varies across disease stages and tissue environments. In acute inflammatory conditions, such as early-stage acute pancreatitis, Treg expansion may represent an adaptive response aimed at limiting tissue injury and restoring immune balance. Nevertheless, excessive immunosuppression during critical windows can impair antimicrobial defence and facilitate bacterial translocation, thereby exacerbating disease severity.24,25 In chronic inflammatory settings, including chronic pancreatitis, sustained immune activation drives progressive tissue damage and fibrosis. Here, Tregs can play a protective role by restraining persistent immune stimulation and limiting fibrogenic type 2 immune responses, particularly through interactions with macrophages, dendritic cells, and innate lymphoid cells.26,27 However, prolonged or dysregulated Treg activity may also contribute to immune exhaustion and impaired tissue regeneration. In cancer, Tregs occupy a more paradoxical position. Within the tumour microenvironment, particularly in pancreatic ductal adenocarcinoma, Tregs are frequently enriched and phenotypically specialised, where they often contribute to immune evasion and resistance by suppressing cytotoxic T-cell function and reinforcing immunosuppressive stromal networks.17,28 At the same time, emerging evidence indicates that complete or non-selective Treg depletion can provoke compensatory inflammatory responses that paradoxically accelerate tumour progression, underscoring the dual and sometimes protective roles of Tregs in restraining tumour-promoting inflammation.17,31 Collectively, these findings suggest that Tregs function not as universal inhibitors of immunity, but as dynamic regulators whose effects depend on tissue context, disease stage, and immune architecture. Understanding this complexity is essential for interpreting the diverse roles of Tregs across pancreatic diseases and for designing therapeutic strategies that modulate—rather than indiscriminately eliminate—Treg function. Regulatory T Cells in Pancreatitis and Pancreatic Cancer Regulatory T Cells in Acute Pancreatitis Acute pancreatitis (AP) is an inflammatory disorder characterised by premature activation of pancreatic enzymes, rapid recruitment of immune cells, and systemic inflammatory responses that may progress to organ failure and death.3,4 Increasing evidence indicates that immune dysregulation—rather than pancreatic injury alone—is a major determinant of disease severity and clinical outcome. Among immune regulators, T-cell dynamics, particularly the balance between effector T cells and regulatory T cells (Tregs), play a critical role in shaping inflammatory progression in AP.35 During the early phase of AP, innate immune activation triggers the release of inflammatory mediators that promote differentiation and activation of CD4⁺ T-cell subsets. The balance between pro-inflammatory Th17 cells and immunosuppressive Tregs has emerged as a key axis governing disease severity.36 Excessive Th17-driven inflammation amplifies neutrophil recruitment and tissue damage, whereas Treg expansion may function as a compensatory mechanism to restrain uncontrolled immune activation and limit pancreatic injury. However, recent studies demonstrate that Treg-mediated immunosuppression in AP is double-edged and highly dependent on timing and tissue context. Glaubitz et al established a murine model of severe acute pancreatitis (SAP) and showed that activation of Foxp3⁺ Tregs promoted disruption of the duodenal barrier, facilitating bacterial translocation into necrotic pancreatic tissue.24 Experimental depletion of Tregs in this model preserved intestinal barrier integrity and reduced bacterial dissemination, indicating that excessive or mistimed Treg activity may paradoxically exacerbate disease severity rather than confer protection. Consistent with these findings, Zhang et al demonstrated that intestinal immune dysregulation is a critical driver of SAP-associated complications. Using an SAP model, they showed that activation of lamina propria dendritic cells and Toll-like receptor 5 (TLR5) signalling in intestinal epithelial cells disrupted T-cell differentiation, leading to Th17/Treg imbalance, impaired barrier function, and enhanced bacterial translocation.25 These observations highlight the gut–pancreas immune axis as a key mediator of systemic complications in AP and underscore the importance of tightly regulated Treg activity during acute inflammation. Clinical and experimental data further suggest that excessive immunosuppression during AP predisposes patients to secondary infections and worsened outcomes.4,35 While transient Treg expansion may be beneficial in limiting early inflammatory damage, sustained or spatially dysregulated Treg responses can suppress antimicrobial immunity, disrupt mucosal defence, and contribute to sepsis and multiple organ dysfunction. Thus, Tregs in AP should be viewed not as uniformly protective cells, but as dynamic regulators whose impact depends on disease stage, localisation, and interaction with other immune subsets. Taken together, these findings indicate that therapeutic modulation of Treg activity in AP requires precise temporal and spatial control. Strategies aimed at restoring immune balance—rather than broadly enhancing or depleting Tregs—may represent a more effective approach to limiting inflammation while preserving barrier integrity and host defence. Targeting the Th17/Treg axis and associated signalling pathways, including intestinal pattern recognition receptors, may offer novel opportunities to mitigate SAP-related complications and improve clinical outcomes.24,25,36 Regulatory T Cells in Chronic Pancreatitis Chronic pancreatitis (CP) is a progressive fibroinflammatory disease characterised by recurrent or persistent pancreatic inflammation that culminates in irreversible parenchymal destruction, stromal remodelling, and functional insufficiency of both exocrine and endocrine compartments.7 Unlike acute pancreatitis, CP reflects a failure to resolve inflammation, leading instead to chronic immune activation, excessive fibrogenesis, and tissue scarring. Increasing evidence indicates that regulatory T cells (Tregs) are critical modulators of this transition from inflammation to fibrosis. Experimental studies have demonstrated that Tregs play a protective and homeostatic role in CP by restraining sustained immune activation and limiting fibrosis. Using a transgenic mouse model of chronic pancreatitis, Glaubitz et al showed that depletion of Foxp3⁺ Tregs resulted in exacerbated pancreatic fibrosis, pronounced stromal deposition, impaired exocrine secretion, and significant weight loss.27 These findings indicate that Tregs actively suppress fibrogenic immune programs and are essential for maintaining immune equilibrium during chronic pancreatic injury. Mechanistically, Tregs mitigate fibrosis in CP by suppressing type-2 immune responses that are known to promote fibroblast activation and extracellular matrix deposition. In particular, Tregs restrain the activity of alternatively activated (M2-like) macrophages, Th2 cells, and innate lymphoid cells type 2 (ILC2s), which collectively drive fibrotic remodelling through secretion of profibrotic cytokines and growth factors.27,37 By limiting dendritic cell maturation and inflammatory cytokine release, Tregs further reduce persistent antigen presentation and downstream immune amplification.38 Clinical observations support a role for Treg dysregulation in specific subtypes of CP. Autoimmune pancreatitis (AIP), a distinct form of CP and part of the IgG4-related disease spectrum, is increasingly recognised as a T-cell-driven disorder.39 Studies suggest that impaired regulatory control and altered CTLA-4-mediated signalling permit excessive effector T-cell activation, leading to tissue inflammation and organ damage.39 These findings underscore that defective Treg function—rather than simple numerical deficiency—may contribute to immune-mediated pancreatic injury in selected CP phenotypes. In addition to modulating cellular immunity, Tregs influence humoral immune responses by regulating B-cell activation and antibody production, further shaping the chronic inflammatory milieu.40 This multi-layered immune regulation highlights the central role of Tregs as coordinators of immune homeostasis rather than passive suppressors. Despite substantial progress, important knowledge gaps remain. The precise molecular mechanisms governing Treg stability, localisation, and functional plasticity in CP are incompletely understood, as is the extent to which Treg-mediated immune suppression may inadvertently contribute to immune exhaustion or impaired tissue regeneration in advanced disease stages. Moreover, most mechanistic insights are derived from animal models, underscoring the need for well-designed human studies integrating immunophenotyping, spatial analysis, and longitudinal clinical data. Collectively, current evidence supports a model in which Tregs serve as key protective regulators in chronic pancreatitis by limiting persistent inflammation and fibrosis. Therapeutic strategies that preserve or restore appropriate Treg function—rather than indiscriminately enhancing or suppressing immune responses—may therefore offer a rational approach to attenuating disease progression and preserving pancreatic function in CP. The chronic immunoregulatory environment shaped by persistent Treg activity in CP may create permissive conditions for malignant transformation, highlighting a potential immunological link between chronic inflammation and pancreatic carcinogenesis. Regulatory T Cells and Immune Escape in Pancreatic Cancer Immune escape is a hallmark of pancreatic cancer and a major barrier to effective immunotherapy.41 PDAC exploits multiple immune evasion mechanisms, including physical exclusion of effector T cells, metabolic constraints, inhibitory cytokine signalling, and dominance of immunosuppressive cell populations—among which Tregs are a central component.28,42 Tregs contribute to immune escape in PDAC through direct suppression of cytotoxic T-cell responses and indirect modulation of other immune and stromal cells. By expressing inhibitory receptors such as CTLA-4 and producing immunosuppressive cytokines, Tregs dampen antigen presentation and effector T-cell activation, thereby reducing tumour immunogenicity.20,22 Additionally, Tregs interact with tumour-associated macrophages and fibroblasts to reinforce immunosuppressive niches within the tumour stroma.43,44 Notably, the role of Foxp3 extends beyond its classical function in Tregs. Aberrant expression of Foxp3 has been detected in pancreatic cancer cells themselves, suggesting a tumour-intrinsic role in immune regulation. Gong et al reported ectopic expression of Foxp3 in pancreatic cancer tissues and cell lines, where it was regulated by TGF-β signalling and influenced cytokine production, including IL-6 and IL-8.45 These findings imply that Foxp3-mediated immunoregulation in PDAC involves both immune and tumour cell compartments. Transforming growth factor-β (TGF-β) signalling further amplifies immune escape in PDAC by promoting Treg differentiation and suppressing effector T-cell function. In a humanised mouse model, Lee et al demonstrated that inhibition of TGF-β2 enhanced IL-2-mediated antitumour T-cell responses and delayed pancreatic tumour growth, underscoring the therapeutic relevance of targeting this axis.46 These data highlight the interconnected nature of Treg biology, cytokine signalling, and tumour progression. Importantly, immune escape in PDAC cannot be attributed to Tregs alone. Instead, it emerges from complex interactions among Tregs, exhausted T cells, myeloid cells, stromal components, and metabolic constraints within the TME.41,44 Consequently, therapeutic strategies aimed at modulating Tregs must account for this broader immune architecture to avoid unintended consequences such as compensatory immunosuppression or tumour-promoting inflammation. In summary, regulatory T cells are a defining feature of the immunosuppressive landscape in pancreatic cancer, yet their role is multifaceted and context-dependent. Selective targeting of tumour-promoting Treg subsets or signalling pathways—rather than global Treg depletion—may offer a more effective and safer approach to overcoming immune escape and improving immunotherapy outcomes in PDAC. Treg Heterogeneity, Spatial Organisation, and Immune Imaging in Pancreatic Cancer Recent single-cell and spatial profiling studies have shown that Tregs in PDAC are not a uniform suppressive population, but comprise heterogeneous subsets with distinct transcriptional programmes, tissue localisation, and functional states. Tumour-infiltrating Tregs may express markers associated with enhanced suppressive activity, tissue residency, and chemokine-driven recruitment, including CTLA-4, CCR8, ICOS, TIGIT, and Helios. These subsets interact closely with exhausted CD8⁺ T cells, tumour-associated macrophages, dendritic cells, cancer-associated fibroblasts, and stromal niches, thereby reinforcing the immunosuppressive architecture of the PDAC microenvironment.32,44,47 This heterogeneity has important therapeutic implications. Global Treg depletion may not reliably improve anti-tumour immunity and may paradoxically promote inflammatory programmes that support pancreatic carcinogenesis. Therefore, current strategies increasingly favour selective targeting of tumour-associated Treg subsets or suppressive pathways while preserving systemic immune tolerance.17,31 Spatially resolved approaches are particularly important because the suppressive effect of Tregs depends not only on their abundance, but also on their proximity to effector T cells, antigen-presenting cells, lymphatic structures, and stromal barriers. In parallel, molecular imaging is emerging as a useful approach for non-invasive evaluation of immune-checkpoint expression and treatment response. PD-L1-targeted near-infrared fluorescence/Cerenkov luminescence imaging has been proposed as a strategy to visualise spatial heterogeneity of immune-checkpoint expression within tumours.48 Similarly, PET/CT has been increasingly explored for monitoring immune-cell therapies, including CAR-T-cell treatment response and immune-related response dynamics, although most evidence remains strongest in haematological malignancies.49 Incorporating immune imaging with single-cell and spatial profiling may therefore improve patient stratification, guide combination immunotherapy, and help identify when and where Treg-directed interventions are most likely to be beneficial. Regulatory T Cells as Therapeutic Targets in Pancreatic Diseases Rationale for Targeting Regulatory T Cells Regulatory T cells are indispensable for maintaining immune tolerance and preventing immune-mediated tissue damage under physiological conditions. However, in pathological states such as pancreatitis and pancreatic cancer, Treg function becomes maladaptive in a disease stage– and context-dependent manner. In acute pancreatitis, transient expansion of Tregs may mitigate excessive inflammation, whereas sustained or mislocalised immunosuppression can impair antimicrobial defence and exacerbate complications. In chronic pancreatitis, Tregs largely exert protective effects by restraining persistent inflammation and fibrosis. In contrast, within the pancreatic cancer microenvironment, Tregs often dominate immune regulation, suppress antitumour immunity, and contribute to resistance against immunotherapeutic interventions.44,47 This duality underscores a fundamental principle: Tregs are not inherently beneficial or harmful, and indiscriminate modulation of their number or function carries substantial risk. Effective therapeutic strategies must therefore aim to fine-tune Treg activity rather than globally enhance or eliminate these cells. Understanding the timing, localisation, and functional heterogeneity of Tregs is essential for safely translating Treg-targeted therapies into clinical practice. Immunotherapeutic Strategies Involving Treg Modulation Immune Checkpoint–Based Approaches Immune checkpoint inhibitors (ICIs), including antibodies targeting CTLA-4 and the PD-1/PD-L1 axis, indirectly modulate Treg function by altering inhibitory signalling pathways shared between Tregs and effector T cells. CTLA-4 blockade can partially deplete or destabilise intratumoural Tregs through Fc-mediated mechanisms, whereas PD-1/PD-L1 inhibition primarily reinvigorates exhausted effector T cells.50,51 Despite their success in several solid tumours, ICIs have shown limited efficacy in pancreatic cancer, largely due to low baseline T-cell infiltration, dense stromal barriers, and redundant immunosuppressive networks dominated by Tregs and myeloid cells.41,44 Importantly, broad checkpoint inhibition carries the risk of immune-related adverse events, including colitis and pancreatitis, highlighting the need for careful patient selection and combination strategies. Current evidence suggests that ICIs may be more effective when combined with approaches that modulate the tumour microenvironment or selectively target tumour-associated Tregs rather than systemic Treg populations. The mechanisms of CTLA-4 and PD-1/PD-L1 checkpoint signalling are schematically illustrated in Figure 3.20,22,50 Figure 3Mechanisms of CTLA-4 and PD-1/PD-L1 immune checkpoint signalling. PD-1 expressed on activated or exhausted T cells binds PD-L1 expressed by tumour cells and antigen-presenting cells, suppressing T-cell receptor signalling, cytokine production, proliferation, and cytotoxic activity, thereby promoting T-cell dysfunction and tumour immune escape. CTLA-4 expressed on regulatory and activated T cells competes with CD28 for CD80/CD86 binding on antigen-presenting cells, reducing co-stimulatory signalling and limiting T-cell activation. These checkpoint pathways collectively attenuate anti-tumour immunity and contribute to immune suppression within the pancreatic tumour microenvironment.The diagram illustrates T cell activation and exhaustion. A dendritic cell interacts with a tumor cell expressing PD-L1, which binds to PD-1 on the T cell. This PD-1/PD-L1 signaling inhibits TCR signaling, reduces PI3K/AKT activity, cytokine production, proliferation and increases apoptosis, leading to T cell exhaustion. This diminishes tumor cell killing, aiding tumor survival. The dendritic cell also expresses CD80/CD86, interacting with CD28 on the T cell to promote activation and maturation. CTLA-4 on the T cell competes with CD28, inhibiting IL-2 production, causing cell cycle arrest and reduced proliferation. Successful T cell activation increases IFN-gamma, IL-2, TNF-alpha, proliferation and survival, enhancing tumor cell killing and immune control. Labels include PD-L1, PD-1, CTLA-4, TCR, CD80/CD86, CD28 and MHC II.Diagram of T cell activation/exhaustion via PD-1/PD-L1, CTLA-4 signaling impacting tumor cell destruction. Mechanisms of CTLA-4 and PD-1/PD-L1 immune checkpoint signalling. PD-1 expressed on activated or exhausted T cells binds PD-L1 expressed by tumour cells and antigen-presenting cells, suppressing T-cell receptor signalling, cytokine production, proliferation, and cytotoxic activity, thereby promoting T-cell dysfunction and tumour immune escape. CTLA-4 expressed on regulatory and activated T cells competes with CD28 for CD80/CD86 binding on antigen-presenting cells, reducing co-stimulatory signalling and limiting T-cell activation. These checkpoint pathways collectively attenuate anti-tumour immunity and contribute to immune suppression within the pancreatic tumour microenvironment. Selective Targeting of Tumour-Associated Treg Subsets Recent advances have identified surface markers and transcriptional signatures that distinguish tumour-resident Tregs from their peripheral counterparts. Molecules such as CCR8, highly expressed on intratumoural Tregs in PDAC, represent promising therapeutic targets that may allow selective depletion or functional inhibition of tumour-promoting Tregs while sparing systemic immune tolerance.52 Such precision approaches aim to overcome immune escape without triggering widespread autoimmunity. In addition to surface markers, targeting cytokine pathways that support Treg stability and recruitment—such as TGF-β signalling—has gained increasing attention. Inhibition of TGF-β can reduce Treg differentiation and restore effector T-cell function, thereby enhancing antitumour immunity in preclinical PDAC models.46 However, given the pleiotropic roles of TGF-β in tissue homeostasis, these strategies require careful dosing and combination with complementary therapies. Cellular Immunotherapies and Their Relationship to Tregs Adoptive cellular therapies, including chimeric antigen receptor (CAR)-T cell and T-cell receptor (TCR)-engineered therapies, offer powerful tools for redirecting immune responses against tumour-specific antigens. In pancreatic cancer, CAR-T and TCR-T strategies targeting mesothelin, Claudin 18.2, and mutant KRAS have shown encouraging signals in early clinical studies.51,53–55 However, their efficacy is often blunted by the immunosuppressive TME, in which Tregs play a dominant role. Rather than viewing Tregs solely as obstacles, emerging strategies aim to reprogram or counterbalance Treg-mediated suppression to enhance the persistence and functionality of engineered T cells. Combination approaches integrating CAR-T or TCR-T therapies with checkpoint blockade, cytokine modulation, or selective Treg targeting may improve antitumour responses while maintaining immune safety. The general workflow of CAR-T cell therapy is illustrated in Figure 4.51,53–55 Figure 4Schematic overview of CAR-T cell therapy with immune-cell surface marker labelling.T cells expressing CD3, with CD4⁺ or CD8⁺ subsets, are isolated from the patient’s peripheral blood and genetically engineered to express a chimeric antigen receptor (CAR). Following ex vivo expansion, CD3⁺CAR⁺ T cells are reinfused into the patient, where they recognise tumour-associated antigens on pancreatic cancer cells, such as mesothelin or Claudin 18.2. CAR–tumour-associated antigen binding activates CAR-T cells and promotes targeted tumour-cell killing through perforin and granzyme B release.The image outlines the CAR-T cell therapy in six steps: A) T cells are isolated from a patient's blood, identified as CD3+, CD4+, or CD8+. B) CAR gene is introduced using viral or non-viral vectors, transforming T cells into CAR-T cells marked as CD3+, CAR+. C) Initial expansion of CAR-T cells occurs. D) Large-scale expansion further increases CAR-T cell numbers. E) Expanded CAR-T cells are reinfused into the patient. F) CAR-T cells recognize and kill tumor cells by binding to antigens like mesothelin or claudin 18.2, releasing perforin and granzyme B to destroy tumor cells. Symbols represent T cells, CAR-T cells, tumor cells, viral vectors, perforin and granzyme B.CAR-T therapy: isolate T cells, add CAR, expand, reinfuse, recognize tumor. Schematic overview of CAR-T cell therapy with immune-cell surface marker labelling.T cells expressing CD3, with CD4⁺ or CD8⁺ subsets, are isolated from the patient’s peripheral blood and genetically engineered to express a chimeric antigen receptor (CAR). Following ex vivo expansion, CD3⁺CAR⁺ T cells are reinfused into the patient, where they recognise tumour-associated antigens on pancreatic cancer cells, such as mesothelin or Claudin 18.2. CAR–tumour-associated antigen binding activates CAR-T cells and promotes targeted tumour-cell killing through perforin and granzyme B release. Therapeutic Considerations Across Pancreatic Disease Stages In pancreatitis, therapeutic modulation of Tregs must prioritise immune balance and tissue protection. During acute disease, strategies that prevent excessive Treg-mediated immunosuppression at critical windows—without abolishing regulatory control—may reduce infectious complications and systemic inflammation.24,35 In chronic pancreatitis, enhancing or stabilising Treg function could attenuate fibrosis and preserve pancreatic function, although long-term consequences require further investigation. In pancreatic cancer, therapeutic success will likely depend on selective, spatially restricted modulation of Tregs in combination with interventions targeting stromal barriers, myeloid suppression, and tumour antigenicity. A one-size-fits-all approach to Treg targeting is unlikely to succeed given the profound heterogeneity of immune landscapes across patients and disease stages. Conclusion and Perspectives Pancreatic diseases encompass a continuum from acute inflammation to chronic fibrosis and malignant transformation, unified by profound immune dysregulation. Across this spectrum, regulatory T cells emerge as central yet paradoxical regulators of immune homeostasis. Rather than acting as uniformly protective or deleterious cells, Tregs exert context-dependent, stage-specific, and spatially defined effects that critically influence disease progression and therapeutic response. In acute pancreatitis, Tregs participate in limiting excessive immune activation, yet excessive or mistimed suppression can impair mucosal barrier integrity and promote infectious complications. In chronic pancreatitis, Tregs predominantly serve protective roles by restraining persistent inflammation and fibrogenic immune circuits, thereby mitigating irreversible tissue damage. In pancreatic cancer, however, specialised Treg populations dominate the tumour microenvironment and contribute to immune escape, therapy resistance, and disease progression—while paradoxically restraining tumour-promoting inflammatory responses in select contexts. These divergent functions underscore a fundamental challenge for immunotherapy: global enhancement or depletion of Tregs is unlikely to yield consistent benefit and may produce unintended consequences. Instead, future therapeutic strategies must prioritise precision—targeting specific Treg subsets, signalling pathways, or spatial niches while preserving systemic immune tolerance. Advances in single-cell and spatial transcriptomics, together with improved immunophenotyping of patient samples, provide unprecedented opportunities to resolve Treg heterogeneity and identify clinically actionable biomarkers. Looking forward, successful translation of Treg-focused therapies in pancreatic diseases will require integrated, stage-aware approaches that combine immune modulation with strategies addressing stromal architecture, microbial influences, and tumour antigenicity. By aligning immunological insight with disease biology, a new generation of therapies may emerge that effectively rebalance immunity without compromising host defence. Such precision immunomodulation holds promise not only for improving outcomes in pancreatic cancer, but also for preventing inflammation-driven disease progression across the broader spectrum of pancreatic disorders.